Status:
COMPLETED
Exercise Prescription for the Improvement of Quality of Life in Elderly Patients With Multiple Myeloma
Lead Sponsor:
Thomas Jefferson University
Conditions:
Plasma Cell Myeloma
Eligibility:
All Genders
65+ years
Phase:
NA
Brief Summary
This trial studies how well exercise prescription works in improving quality of life in elderly patients with multiple myeloma. Engaging and adhering to an exercise program may improve functional stat...
Detailed Description
PRIMARY OBJECTIVE: I. Assess the ability for elderly multiple myeloma patients to maintain a personalized exercise regimen and activity level for a period of 6 months. SECONDARY OBJECTIVE: I. Asses...
Eligibility Criteria
Inclusion
- Diagnosis of multiple myeloma
- If patients are undergoing an autologous stem cell transplant, then they will be enrolled after their transplant so that there is not an interruption in the study period
- Patients are eligible whether or not they have lytic bone lesions
- If they do have lytic lesions, the lesions must be low risk for fracture (low risk by Mirel's score or less than 50% of vertebral body height)
- If patients are high risk for bone fracture, they must undergo bone stabilization prior to being considered for enrollment
- Patients will have to be at least 6 weeks from date of stabilization
- Provide signed and dated informed consent form
- Willing to comply with all study procedures and be available for the duration of the study
- Subjects need to be within 24 months of their multiple myeloma diagnosis
- Subject must be able to stand and walk to perform baseline assessments
- Subjects must be able to text message (will need cell phone)
- Need to limit to able to read and understand English as video visit capability is only in English at this point in time and multiple questionnaires will not be translated into other languages
Exclusion
- Presence of lytic lesions that cannot undergo appropriate stabilization
- Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study
- Non English speaking
- Diagnosed greater than 24 months prior to screening
Key Trial Info
Start Date :
October 24 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 27 2022
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT04100044
Start Date
October 24 2019
End Date
May 27 2022
Last Update
April 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107